Nanobiotix

Equities

NANO

FR0011341205

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:35:04 2024-04-24 am EDT			5-day change	1st Jan Change
5.535 ^EUR	-3.74%		+2.50%	-16.64%

Apr. 24	Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 03	Nanobiotix completes escalation portion of 2020-0123 study	CF

Nanobiotix S.A. Reports Earnings Results for the Half Year Ended June 30, 2021

September 08, 2021 at 04:15 pm EDT

Nanobiotix S.A. Announced earnings results for the half year ended June 30, 2021. For the half year, the company announced total revenue was EUR 1.319 million compared to EUR 1.448 million a year ago. Operating loss was EUR 29.778 million compared to EUR 18.384 million a year ago. Net loss was EUR 30.420 million compared to EUR 20.579 million a year ago.

Latest news about Nanobiotix

Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 24	CI
Nanobiotix completes escalation portion of 2020-0123 study	Apr. 03	CF
Nanobiotix Completes Dose Escalation Segment of Phase 1 Study Targeting Non-Small Cell Lung Cancer	Apr. 02	MT
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommends Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation	Apr. 02	CI
Nanobiotix Gets $20 Million Milestone Payment in Phase 3 Trial for Potential Head, Neck Cancer Drug	Jan. 30	MT
Nanobiotix: targets achieved for NANORAY-312	Jan. 30	CF
Nanobiotix Gets $20 Million Milestone Payment from Janssen	Jan. 30	MT
Nanobiotix: transfer of NBTXR3 rights in Asia	Dec. 27	CF
Nanobiotix Partner Transfers Asian Commercialization Rights for Oncology Therapy to Johnson & Johnson Unit	Dec. 27	MT
LianBio Assigns Rights to Nanobiotix's Oncology Therapy in China, Other Asian Markets to Janssen Pharmaceutica	Dec. 26	MT
ADRs Advance, Argo Blockchain PLC Climbs 35.0%	Dec. 22	DJ
Valneva Shareholders OK One-tier Governance Model; New Chair Appointed	Dec. 21	MT
Nanobiotix: closing of remaining JJDC placement	Dec. 05	CF
Nanobiotix Closes Issuance of Additional Shares to Johnson & Johnson Innovation – JJDC	Dec. 05	MT
Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.	Dec. 03	CI
Johnson & Johnson Discloses Stake in Nanobiotix	Nov. 17	MT
Transcript : Nanobiotix S.A., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Nanobiotix Raises EUR50.9 Million via Global Follow-on Offering	Nov. 08	MT
But where have the bears gone?	Nov. 03
ADRs Advance; Trivago N.V. Climbs 86.6%	Nov. 02	DJ
Nanobiotix Prices $55 Million Share Sale in US, Europe; Paris Stock Closes Lower	Nov. 02	MT
The Fed doesn't want to raise rates (but is pretending to)	Nov. 02
Nanobiotix launches global offering	Nov. 02	CF
Nanobiotix Seeks $30 Million from Global Share Sale	Nov. 02	MT
Nanobiotix S.A. announced that it expects to receive $25 million in funding from Johnson & Johnson Innovation - JJDC, Inc.	Oct. 31	CI

Chart Nanobiotix

Duration

Period

More charts

Company Profile

Nanobiotix is a pioneer and leader in nanomedicine that has developed a revolutionary approach to the treatment of cancer. The company focuses its effort on the development of its products portfolio entirely patented, NanoXray, innovation based on the physical mode of action of nanoparticles that, under the action of radiation, allow maximizing the absorption of X-rays inside the cancer cells without increasing the dose received by the surrounding healthy tissue. NanoXray products are compatible with standard radiotherapy treatments and are intended to potentially treat a wide variety of cancers via multiple routes of administration. The company's resources are primarily devoted to the development of its lead product candidate: NBTXR3, which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®.

Sector

Biotechnology & Medical Research

Calendar

08:00am - Q4 2023 Earnings Call

More about the company

Income Statement Evolution

More financial data

Ratings for Nanobiotix

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.535 EUR

Average target price

11.3 EUR

Spread / Average Target

+104.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NANOBIOTIX	-16.64%	290M
IQVIA HOLDINGS INC.	+4.09%	43.43B
LONZA GROUP AG	+47.81%	41.69B
MODERNA, INC.	+9.45%	41.31B
CELLTRION, INC.	-10.92%	27.14B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.47B
MEDPACE HOLDINGS, INC.	+29.70%	12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.33B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.03B

Other Biotechnology & Medical Research